Overview

Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial

Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this prospective, single-center randomized controlled trial is to identify the optimal adjuvant intravesical therapy in patients with intermediate risk (IR) non muscle invasive bladder cancer by comparing two commonly utilized intravesical regimens; intravesical immunotherapy (BCG) and intravesical chemotherapy.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mansoura University
Treatments:
Epirubicin
Criteria
Inclusion Criteria:

- 1- Adult patients (aged >18 years) 2- Patients with primary or recurrent papillary
NMIBC. 3- Complete TURBT. 4- Patients with IR NMIBC confirmed by histopathology.

Exclusion Criteria:

- 1. Inability to give informed consent. 2. Patients with history of previous
radiotherapy or systemic chemotherapy. 3. Patients suffering from immuno-deficiency or
other malignancies. 4. Patients with history of hypersensitivity reaction to BCG or
epirubicin. 5. Examination under anesthesia (EUA) reveals palpable bladder mass. 6.
Patients with low or high risk NMIBC by histopathology